Research progress on Astragalus active ingredient in treatment of hepatic fibrosis based on cell signaling pathway / 中国药理学通报
Chinese Pharmacological Bulletin
;
(12): 18-23, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-1013873
ABSTRACT
Hepatic fibrosis is present in most chronic liver disease processes, and there are no ideal anti-fibrotic drugs available. Astragalus has a long history of medicinal use, and its anti-fibrotic effects have been confirmed by modern studies. In this study we have searched the literature to identify the signaling pathways and mechanisms of action of Astragalus and its active ingredients on hepatic fibrosis in recent years, so as to provide the basis and ideas for the development of anti-fibrotic drugs and mechanisms of Astragalus. It is showed that the active ingredients of Astragalus act through regulating p38MAPK, TGF-pl/Smads,NF-
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Pharmacological Bulletin
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS